UK: Earn-Outs On Trial

Last Updated: 17 April 2012
Article by Baljit Chohan and Kevin Jones

Originally published in the December issue of PLC magazine.

There may be a sting in the tail

The recent High Court decision in Porton Capital Technology Funds and others v 3M UK Holdings Limited and another shows that agreeing to an earn-out as part of the purchase price for a business does not always produce the desired result ([2011] EWHC 2895 (Comm)) (see box "What is an earnout"). Expectations on both sides may often be far too high.

The case also illustrates the dangers of relying on the common contractual compromise of "consent not to be unreasonably withheld".

What is an earn-out?

An earn-out is a means of ensuring that buyers do not overpay for (and sellers do not undersell) businesses that may be diffi cult to value upfront. Part of the purchase price is paid on completion of the acquisition, with the balance dependant on the future performance of the target business.

An earn-out is often used as a management incentive where owner-managed businesses are sold and the managers continue to work in the business following the sale.

Earn-outs are a common feature of acquisitions in the biomedical sector. The value of businesses in the sector is often dependant on the successful development, testing, regulatory approval and launch of a product in one or more territories.

The transaction

Acolyte had developed a product for detecting the presence of the antibiotic-resistant "superbug", MRSA, in hospital patients. The product, called "BacLite", was expected to be attractive to hospitals, as it produced faster results than the cheapest competing products but cost less than the fastest test processes. BacLite had been approved for sale throughout the EU and had actually been sold to a small number of hospitals in the UK.

US multinational 3M believed that BacLite might also be sold successfully in other major markets, such as the rest of the EU, the US, Canada and Australia. It offered, through a UK subsidiary, to acquire Acolyte for an initial price of £10.4 million. The earn-out offered further consideration equal to 100% of revenue from worldwide sales of BacLite during 2009, to a maximum of £41 million (less incentive payments to the sales force).

All those involved knew that the earnout payments might ultimately be far lower than the maximum and were dependant on BacLite's success. The sellers were not prepared to leave that success wholly to chance and negotiated terms in the sale agreement that 3M would:

  • "Actively market" BacLite and would "diligently" seek regulatory approval for its sale in the US, Canada and Australia.
  • Devote the same marketing and other resources to BacLite as to its other medical products and remunerate its sales team on the same basis as other product teams.
  • Not shut down the Acolyte business without the sellers' consent, "which shall not be unreasonably withheld".

3M, for its part, insisted on a provision stating that it was not obliged to operate its business in a manner that increased the earn-out payments.

The dispute

Almost immediately after completion, things began to go wrong. Clinical trials in the US produced consistently much less accurate results than the trials carried out by Acolyte in the UK before the acquisition. This was against a background of very substantial expenditure by 3M in setting up new manufacturing facilities, and in product development and sales efforts.

The one market in which sales had been achieved was the UK. However, the UK government announced in October 2007 that it would introduce MRSA screening for all elective hospital admissions in 2008. This was likely to lead hospitals to buy the cheapest products because of the sheer number of tests that would be needed, making BacLite's "mid-range" product far less attractive. The market for BacLite was in danger of disappearing entirely.

By the end of March 2008, testing and approval for launch in the US and Canada had been put on hold and some of the EU sales team were reassigned to other products.

In July 2008, 3M made the first approach to the sellers for consent to shut down Acolyte in exchange for a payment of just over $1 million. This was refused, and the sellers demanded the maximum earn-out payment of £41 million in exchange for consent to cease business.

3M contended that this refusal meant that the sellers were unreasonably withholding their consent, in breach of the sale agreement. The sellers countered that 3M was in breach of that agreement because it had neither "actively marketed", nor "diligently" sought the relevant regulatory approvals for, BacLite.

The decision

The trial lasted for almost a month in total, with around 20 witnesses, including experts, mountains of written evidence, a 65-page judgment and (no doubt) very substantial costs.

The High Court concluded that:

  • From March 2008, 3M was no longer diligently seeking regulatory approval in the US and was thus in breach of the sale agreement.
  • From various dates between June 2008 and February 2009, 3M had ceased active marketing of BacLite in the EU, the US, Canada and Australia, also in breach of the sale agreement.
  • The sellers had not unreasonably refused consent to shut down Acolyte; they were not required to balance the costs incurred by 3M against their interest in receiving the maximum possible earn-out payment. It was for 3M to prove unreasonableness (for example, that the refusal was due to some ulterior motive) and it had not done so.

In the absence of the sale agreement, it might have been a reasonable commercial decision, on the facts, for 3M to close down Acolyte, but that is a different issue to the question of whether or not it was unreasonable for the sellers to withhold consent to the closure.

The court was then left to reach its best estimate of what the actual sales of BacLite would have been had 3M kept its side of the bargain. The sellers were awarded just over $2 million, more than double 3M's original offer, but well short of the £41 million which the sellers had originally hoped for.

Practical implications

The decision highlights the uncertainties for both buyers and sellers of agreeing to an earn-out. In agreeing the financial parameters, it is crucial to consider how realistic the underlying sales or other financial projections are, and what might happen to the market in any interval between the date of sale and the earn-out kicking in to change the picture. The buyer should check that it is not locked in to continuing indefinitely with an obviously struggling business, regardless of the costs of doing so. Both parties should ensure that they are properly protected from any underhand manipulation of the business that would affect the amount payable.

The decision also illustrates that while "consent not to be unreasonably withheld" is a compromise that has allowed numerous contract negotiations to be closed, it sets a challenge in which the party alleging unreasonableness will have to prove it. Although it may be difficult to find an alternative consent wording acceptable to all parties, they should at least consider if there are any specific circumstances in which consent either cannot be refused or is deemed to be given.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.